Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Royalty just keeps going higher… I love that whole business where they help fund bio, and they get the returns. It's a terrific company. I remember when GA brought it public, and I liked it then, I like it now. Stock market data. Photo by Alesia Kozik on Pexels Royalty Pharma plc (NASDAQ:RPRX) makes money by buying up royalties for multiple drugs and funding new research in the biotech world. Its current line-up includes a vast number of treatments from cancer to rare diseases. On January 11, the company announced that it had entered into a funding agreement with Teva Pharmaceuticals to accelerate the clinical development of TEV-‘408, an anti-IL-15 antibody targeting several autoimmune diseases. CEO and Chairman of the Board of Royalty Pharma plc (NASDAQ:RPRX), Pablo Legorreta, said: Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Roy
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.MarketBeat
- Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]CNBC
- Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026GlobeNewswire
RPRX
Sec Filings
- 1/26/26 - Form 4
- 1/23/26 - Form 4
- 1/20/26 - Form 4
- RPRX's page on the SEC website